Relmada Therapeutics downgraded by Goldman with a new price target
$RLMD
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/17/2024 | $3.50 → $13.00 | Hold → Buy | Jefferies |
| 6/5/2024 | $3.00 → $2.00 | Neutral → Sell | Goldman |
| 10/14/2022 | $81.00 → $8.00 | Buy → Neutral | Goldman |
| 10/14/2022 | $90.00 → $10.00 | Buy → Hold | Truist |
| 10/14/2022 | Buy → Neutral | Guggenheim | |
| 10/13/2022 | $64.00 → $7.00 | Outperform → Perform | Oppenheimer |
| 12/20/2021 | $50.00 → $42.00 | Outperform | SVB Leerink |
| 11/18/2021 | $50.00 | Buy | Mizuho |
CORAL GABLES, Fla., Jan. 12, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Fabiana Fedeli, Chief Investment Officer Equities, Multi Asset and Sustainability, at M&G Investments, one of the United Kingdom's largest and longest established investment houses, as an independent director to the Company's Board of Directors. Ms. Fedeli has extensive knowledge of international capital markets, sustainability, governance and corporate strategy
CORAL GABLES, Fla., Jan. 9, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of Cedric O'Gorman MD as the Company's Chief Medical Officer. Dr. O'Gorman will lead medical, clinical and regulatory functions in support of the Company's late-stage REL-1017 development program. Dr. O'Gorman brings to Relmada more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, with significant expertise
Company Continues Commercial Preparations in Advance of Phase III Clinical Trial Readouts for REL-1017 in Major Depressive Disorder Expected in 2022 CORAL GABLES, Fla., July 21, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of John Hixon to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. "My due diligence performed before joi
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, ", Relmada", , ", the Company", )), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for th
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. Conference Call and Webcast Information:Date: Thursday, November 7, 2024 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Conference ID Code: 60579Webcast Access: Click Here A replay of the webcast will be available in the Investors
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
Relmada Therapeutics, Inc. (NASDAQ:RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the publication of REL-1017 clinical data from the Reliance I Study in the peer-reviewed journal, The Journal of Clinical Psychiatry. The article is titled, "Efficacy and Safety of Esmethadone (REL-1017) in Patients with Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial", and is available online at Link To Title.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for HealthEquity, Inc. (NASDAQ:HQY) from $95 to $100. Keybanc analyst Scott Schoenhaus maintained an Overweight rating. HealthEquity shares gained 2.7% to close at $83.40 on Tuesday. See how other analysts view this stock. HC Wainwright & Co. boosted the price target for HOOKIPA Pharma Inc. (NASDAQ:HOOK) from $5 to $6. HC Wainwright & Co. analyst Arthur He maintained a Buy rating. HOOKIPA Pharma shares fell 8.1% to close at $0.7990 on Tuesday. See how other analysts
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
Jefferies upgraded Relmada Therapeutics from Hold to Buy and set a new price target of $13.00 from $3.50 previously
Goldman downgraded Relmada Therapeutics from Neutral to Sell and set a new price target of $2.00 from $3.00 previously
Goldman downgraded Relmada Therapeutics from Buy to Neutral and set a new price target of $8.00 from $81.00 previously
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, ", Relmada", , ", the Company", )), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for th
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. Conference Call and Webcast Information:Date: Thursday, November 7, 2024 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Conference ID Code: 60579Webcast Access: Click Here A replay of the webcast will be available in the Investors
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
SC 13G/A - RELMADA THERAPEUTICS, INC. (0001553643) (Subject)
10-Q - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
EFFECT - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)
S-3 - RELMADA THERAPEUTICS, INC. (0001553643) (Filer)